The use of trimethoprim-sulfamethoxazole in the treatment of chest infections.
The use of combinations of trimethoprim (TMP) and sulfamethoxazole (SMZ) for the treatment of chest infections is described. A number of studies have shown that TMP-SMZ is effective treatment for exacerbations of chronic bronchitis. The long-term use of TMP-SMZ as chemoprophylaxis of chronic bronchitis is also described. Conventional doses of TMP-SMZ (320 mg of TMP and 1600 mg of SMZ) have proved most effective in the prevention of chronic bronchitis; the drug combination is nontoxic and does not lead to the emergence of any resistant organisms. The use of TMP-SMZ for the treatment of pneumonia has been previously described. TMP-SMZ has also been found effective for long-term use in the treatment of cystic fibrosis.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D001987:Bronchiectasis / Q000188:drug therapy; D001991:Bronchitis / Q000150:complications; D002908:Chronic Disease; D003550:Cystic Fibrosis / Q000188:drug therapy; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy; D012140:Respiratory Tract Diseases / Q000188:drug therapy; D013420:Sulfamethoxazole / Q000627:therapeutic use*; D014295:Trimethoprim / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D004338:Drug Combinations; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole